Author

Gabriela M. Stiegler

Observed names: G Stiegler, G. Stiegler, Gabriela Stiegler

Observed institutions: Tulane University, University of Vienna, Duke University, Polymun (Austria), Dana-Farber Cancer Institute, Center for Cancer Research, BOKU University

OpenAlex ID: A5042369547

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

2000 · John R. Mascola, Gabriela Stiegler, et al. · Nature Medicine · 1,260

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection

2000 · Timothy W. Baba, Vladimir Liska, et al. · Nature Medicine · 875

Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41

2001 · Michael B. Zwick, Aran F. Labrijn, et al. · Journal of Virology · 812

Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

1999 · John R. Mascola, Mark G. Lewis, et al. · Journal of Virology · 788

PDF

Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

2005 · Barton F. Haynes, Judith Fleming, et al. · Science · 762

Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies

2004 · James M. Binley, Terri Wrin, et al. · Journal of Virology · 713

A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1

2001 · Gabriela Stiegler, Renate Kunert, et al. · AIDS Research and Human Retroviruses · 529

Generation of glyco‐engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human‐like N‐glycan structure

2008 · Richard Strasser, Johannes Stadlmann, et al. · Plant Biotechnology Journal · 528

PDF

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

2005 · Alexandra Trkola, Herbert Kuster, et al. · Nature Medicine · 513

Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1

2004 · Michael B. Zwick, Richard Jensen, et al. · Journal of Virology · 279

Regulatory approval and a first‐in‐human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants

2015 · Julian K‐C. Ma, Jürgen Drossard, et al. · Plant Biotechnology Journal · 265

PDF

Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV‐1 and contains predominantly single‐GlcNAc N ‐glycans

2007 · Thomas Rademacher, Markus Sack, et al. · Plant Biotechnology Journal · 178

PDF

Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge

2001 · Regina Hofmann-Lehmann, Josef Vlasak, et al. · Journal of Virology · 164

Complete Protection of Neonatal Rhesus Macaques against Oral Exposure to Pathogenic Simian‐Human Immunodeficiency Virus by Human Anti‐HIV Monoclonal Antibodies

2004 · Flavia Ferrantelli, Robert A. Rasmussen, et al. · The Journal of Infectious Diseases · 163

Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies

2001 · Michael B. Zwick, Meng Wang, et al. · Journal of Virology · 160

Cost-effective production of a vaginal protein microbicide to prevent HIV transmission

2008 · Koreen Ramessar, Thomas Rademacher, et al. · Proceedings of the National Academy of Sciences · 157

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1

2002 · Christine Armbruster, Gabriela M. Stiegler, et al. · AIDS · 131

Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection

2007 · Saurabh Mehandru, Brigitta Vcelar, et al. · Journal of Virology · 124

Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques

2003 · Flavia Ferrantelli, Regina Hofmann-Lehmann, et al. · AIDS · 113

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

2004 · Christine Armbruster, Gabriela M. Stiegler, et al. · Journal of Antimicrobial Chemotherapy · 110

Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry

2001 · Markus Hildinger, Matthias T. Dittmar, et al. · Journal of Virology · 110

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans

2002 · Gabriela Stiegler, Christine Armbruster, et al. · AIDS · 109

In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10

2007 · Amapola Manrique, Peter Rusert, et al. · Journal of Virology · 100

Characterization of Human Class-Switched Polymeric (Immunoglobulin M [IgM] and IgA) Anti-Human Immunodeficiency Virus Type 1 Antibodies 2F5 and 2G12

2003 · Susanne Wolbank, Renate Kunert, et al. · Journal of Virology · 99

Functional analysis of the broadly neutralizing human anti‐HIV‐1 antibody 2F5 produced in transgenic BY‐2 suspension cultures

2007 · Markus Sack, Antje Paetz, et al. · The FASEB Journal · 89

Works count: 63

Citation count: 10,430

H-index: 41

I10-index: 52